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Abstract: Glibenclamide (Glyburide), a widely used second-generation sulfonylurea hypoglycemic agent, is a known specific blocker
of adenosine triphosphate (ATP) sensitive potassium (K+) channels. Although the blockage of the ATP dependent potassium channel
reduces arrhythmia, it increases enfarct size. Yohimbine is an alpha-2 blocker that reduces infarct size as suggested by several
studies. We hypothesized that a combination of yohimbine and glibenclamide may be more effective in reducing the arrhythmia
following ligation. The arteria descendence (LAD) branch of the left coronary artery in conscious rats was ligated and arrhythmia
was recorded during the 15 min following coronary ligation. Sixteen hours after coronary ligation, infarcted myocardium was
determined by histological analysis. One and five mg/kg of yohimbine and 5mg/kg of glibenclamide were given intraperitoneally 25
min before ligation. Yohimbine in a 5 mg/kg dosage reduced both the occurrence and the duration of ventricular fibrillation (VF) and
ventricular tachycardia. The combination of yohimbine and glibenclamide did not exhibit any additive or synergistic effects on the
antiarrhythmic effect of each drug alone following coronary ligation. Moreover, yohimbine in 5mg/kg doses and a combination of 1
mg/kg of yohimbine and glibenclamide increased the survival rate after coronary ligation compared to the non-treated group. The
combination of glybenclamide with yohimbine had no clear additive effects such as reducing arrhythmia following cooronary ligation.
The antiarrhythmia produced by glibenclamide may not only depend on the blockage of the ATP dependent potassium channels, but
also on adrenergic preconditioning.
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Introduction
The modulation of adenosine triphosphate (ATP)
dependent potassium channels plays an important role in
the suppression of arrhythmias following coronary
ligation. Although there are several studies indicating that
blockage of the channel reduces the propensity to
arrhythmias (1-6), others maintain that it is
proarrhythmic (7-9). One of the deleterious effects of
glibenclamide is on infarct size. It increases infarct size as
well as reducing arrhythmia. The increased infarct size
induced by glibenclamide may be due to increased calcium
overload and contraction. In our previous study, we used
the beta adrenergic selective blocker metoprolol to
reduce the ischemic effect of glibenclamide (10). In that
study metoprolol in combination with glibenclamide was

very effective in reducing the incidence of lethal
arrhythmia. Metoprolol is a cardioselective beta
adrenergic blocker and reduces heart rate and
contraction. On the other hand, yohimbine is an alpha-2
adrenergic blocker and increases heart rate. Although
these 2 drugs have an adverse effect on heart rate, it has
suggested by several studies that yohimbine reduces
infarct size and the intensity of ventricular fibrillation
following coronary ligation (11-14). Since yohimbine
reduces infarct size, the combination of glibenclamide
with yohimbine may be effective in reducing ischemia
induced arrhythmia.
In the present study, our aim was to research the
effect of yohimbine, alone or in combination with
glibenclamide on arrhythmia and survival rate following
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acute coronary ligation. No studies investigating the
effect of glibenclamide in combination with an alpha-2
adrenergic blocker on arrhythmia following coronary
ligation have been found.

Materials and Methods
Fifty four male Sprague-Dawley rats weighing 232330 g were used. The animals were fed on commercial
rat food pellets and were allowed to drink tap water ad
libitum. All the animals were treated in accordance with
the guiding principles in the care and handling of animals
as recommended by of Helsinki Declaration.
In preliminary surgery, a loose loop of atraumatic silk
was placed around the left main coronary artery about 2
mm from its origin under ether anesthesia. The silk was
passed through polyethylene tubing and the chest was
closed, with the tubing remaining inside the thoracic
cavity (15). The animals recovered immediately following
the operation. Sometimes, however, artificial respiration
(60 strokes/min, Ugo Basile Italy) with room air was
performed through the mouth as animals were in deep
anesthesia after the operation, and this was maintained
until spontaneous respiration resumed. After 6-7 days of
coronary artery ligation, the 2 ends of the loose silk loop
were freed through a small incision in the skin, and
electrodes were placed on both sides of the chest wall
under ether anesthesia. The animals were given
approximately 2 h to recover from the ether anesthesia
and to adapt to their new conditions. The electrodes were
connected to a recording system (Power Lab/4s, UK), and
the silk ligature was tightened to produce coronary artery
ligation in freely moving, conscious animals.
A bipolar ECG recording was made during the first 15
min after coronary ligation and stored on computer for
later analysis. Approximately 16 h following the ligation,
the animals were anesthetized with pentothal (60 mg/kg
i.p.) and heparinized through the vena saphena. The heart
was excised and washed in isotonic solution. The atria of
the heart were removed and only the ventricles were left.
The ventricles were sliced into 1 mm thick transversal
sections and were stained in 0.1% nitroblue-tetrazolium
dye. The wet weight of the infarcted, unstained
myocardium was measured and expressed as a
percentage of the total weight of the ventricles.
Heart rate was calculated from the ECG recordings
for each animal before and after ligation at regular
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intervals. The incidence and duration of arrhythmia
observed during the 15 min following coronary ligation
were measured. The arrhythmias were identified as
ventricular fibrillation (VF), ventricular tachycardia (VT),
and other types of arrhythmia including single VEBs,
bigeminia and salvos according to the Lambeth
conventions (16). An arrhythmia score was given
according to the incidence and duration of arhythmias for
each animal as follows: 0 = no arrhythmia; 1 = < 10 s VT
or other arrhythmia, no VF; 2 = 11-30 s VT or other
arrhythmia, no VF; 3 = 31-90 s VT or other arrhythmia,
no VF; 4 = 91-180 s VT or other arrhythmia and/or < 10
s reversible VF; 5 = > 180 s VT or other arrhythmia
and/or > 10 s reversible VF; 6 = irreversible VF.
Drug treatment: glibenclamide (Sigma) was dissolved
in a 1:1 mixture of dimethylsulfoxide and ethanol and was
applied i.p. at a dose of 5 mg/kg and in a volume of 100
ul/kg. Yohimbine (Sigma) was dissolved in isotonic saline
solution and given i.p. at a dose of 1-5 mg/kg and in a
volume of 1 ml/kg. The control animals were given 1
ml/kg of isotonic saline solution and 0.1 ml/kg of the
solvent for glibenclamide. All injections were performed
25 min before coronary ligation.
Determination of blood glucose concentrations: a
single drop of blood was taken to determine blood
glucose by cutting the tip of the tail. Blood glucose was
measured by a strip test (Glucotrend 2, Roche Group,
UK) before coronary ligation in 5 animals in each group
to assess hypoglycemia.
Statistical analysis: the survival rate and incidence of
arrhythmias were compared by chi-square test. The other
parameters were expressed as mean ± SE, and after
analyses of variance, one way ANOVA (post hoc test,
LSD), were compared by Student’s t-test (unpaired-2tailed).

Results
ST segment elevation was observed immediately
following ligation. Animals with unsuccessful ligation (23
animals), did not exhibit ST segment elevation or QRS
changes and pressure decline after ligation, and no infarct
was determined after 16 h. Forteen of the animals died
from bleeding or respiratory failure at the end of the
preliminary operation. These animals were excluded from
the study.
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yohimbine. Heart rate following ligation was also lowest
in this group.

Glibenclamide pretreatment lowered the heart rate
before coronary ligation (Table 1). Heart rate increased
following ligation in all groups, except in animals given 5
mg/kg of yohimbine alone and in combination with
glibenclamide. The heart rates in the following minutes
were not different from those of the control.

Although glibenclamide alone did not influence the
incidence of arrhythmia, the survival rate at the end of 16
h of coronary ligation was significantly higher after
combining glibenclamide with yohimbine (1 mg/kg)
(Table 2). In combination with the higher dose of
yohimbine, glibenclamide nonsignificantly increased the
survival rate. Yohimbine alone in a 5 mg/kg dose
increased the survival rate and nonsignificantly reduced
total arrhythmic periods, but not in the smaller dose. The
arrhythmia score was also significantly lower in this
group (P < 0.05) (Table 3).

Coronary artery ligation in conscious rats resulted in
severe arrhythmias that usually appeared between the
th
th
3rd and 5 mins and reached maximal severity at the 6
min of coronary ligation. If the animals survived, these
arrhythmias disappeared and sinusal rhythm resumed
after 12 min of coronary ligation. No differences were
found in the incidence of arrhythmia among the groups.
However the incidence of ventricular fibrillation was
nonsignificantly lowest in the group treated with 5mg of

The duration of ventricular fibrillation during the 15
min following coronary ligation was shortened

Table 1. Heart rate before and following coronary ligation (Mean± Standard error).
Heart rate / min
Grups
Before ligation

1 min

3 min

5 min

8 min

12 min

15 min

Control

432 ± 16

479 ± 15

439 ± 21

434 ± 37

464 ± 27

462 ± 17

459 ± 14

Glibenclamide 5 mg/kg

354 ± 15*

435 ± 18

421 ± 19

400 ± 10

425 ± 23

388 ± 13

392 ± 15

Yohimbine 1 mg/kg

458 ± 18

504 ± 10

478 ± 13

471 ± 5

457 ± 22

403 ± 21

382 ± 18

Yohimbine 5 mg/kg

487 ± 10*

453 ± 11

416 ± 14

422 ± 16

415 ± 11

410 ± 6

394 ± 12

Glibenclamide 5 mg/kg +
Yohimbine 1 mg/kg
Glibenclamid 5 mg/kg +
Yohimbine 5 mg/kg

453 ± 11

496 ± 7

490 ± 7

493 ± 10

445 ± 19

445 ± 19

454 ± 24

450 ± 17

419 ± 33*

423 ± 25

467 ± 25

419 ± 15

419 ± 15

427 ± 31

*P < 0.05

N = Number of animals

Table 2 The survival rate and incedence of arrhythmia following coronary ligation.
Dose,
mg/kg

Control

n

Surviving
15 min
n/%

Surviving
16 h
n/%

Incidence of arrhythmia (n /%)
None

VF

VT

Others

Bradycar.

14

8/57

4/28

0

9/64

11/79

14/100

1/7

Glibenclamide 5 mg/kg

5

10

8/80

7/70

0

5/50

10/100

10/100

1/10

Yohimbine 1mg/kg

1

9

5/55

4/44

1/11

5/55

7/78

8/89

2/22

Yohimbine, 5 mg/kg

5

7

6/86

6/86*

1/14

2/29

3/42

6/86

1/13

5+1

7

6/86

6/86*

0

4/57

7/100

7/100

1/14

5+5

7

6/86

5/71

0

4/57

6/86

7/100

2/29

Glibenclamide 5 mg/kg +
Yohimbine 1 mg/kg
Glibenclamide 5 mg/kg +
Yohimbine 5 mg/kg

Significantly different (*P < 0.05) from control
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Table 3. The duration of total arrhythmias observed during 15 minutes following coronary ligation and arrythmia score.
Mean±Standart error
Duration of arrhythmias (seconds)
N

Arrythmia score
VF

VT

Others

Total

Control

14

267 ± 96

60 ± 40

65 ± 47

393 ± 95

4.5 ± 0.4

Glibenclamide 5 mg/kg

10

79 ± 25

48 ± 25

62 ± 16

314 ± 113

3.8 ± 0.4

Yohimbine 1 mg/kg

9

232 ± 112

84 ± 56

14 ± 4

331 ± 111

4.4 ± 0.7

Yohimbine 5 mg/kg

7

114 ± 93

26 ± 9

11 ± 3

145 ± 102f

2.5 ±0.8*

Glibenclamide 5 mg/kg + Yohimbine 1 mg/kg

7

94 ± 91

54 ± 18

42 ± 6

190 ± 79

4.1 ±0.8

Glibenclamide 5 mg/kg + Yohimbine 5 mg/kg

7

27 ± 13j

80 ± 24

84 ± 25

191 ± 47

4.4 ± 0.9

*P < 0.05
jP = 0.07,fP = 0.08 compared with the corresponding control value

nonsignificantly when a combination of 5 mg/kg of
glibenclamide and 5 mg/kg of yohimbine was given (P <
0.05) (Table 3), but was not different in the animals that
survived (Table 4). Glibenclamide alone and in
combination with 5 mg of yohimbine nonsignificantly
reduced the duration of ventricular fibrillation, but was
not so effective in lowering arrhythmia when combined
with a 1 mg/kg dose of yohimbine. There were no
synergic effects on arrhythmia between yohimbine and
glibenclamide, since there was no difference between the
glibenclamide and glibenclamide plus yohimbine
combinations in the arrhythmic period and the length of
individual arrhythmia appeared following ligation.
Yohimbine alone, in a 5 mg dose, lowered the duration of
ventricular fibrillation and the arrhythmia score. This
level of yohimbine was not effective in reducing the
arrhythmia score in combination with glibenclamide.
Infarct size decreased only in rats treated with 5 mg
of yohimbine compared to the control in surviving
animals 16 h following coronary ligation (Table 3). This
was associated with the less severe arrhythmia observed
in this group. Glibenclamide alone or in combination with
yohimbine had no effect on the infarct size.
Blood glucose concentrations were lowered by
glibenclamide. Yohimbine alone did not change plasma
glucose levels although it potentiated the hypoglycemic
effect of glibenclamide, (Table 5). There was no
correlation between increased heart rate and low blood
glucose.
24

Discussion
The results demonstrate that yohimbine pretreatment
alone significantly (P < 0.05) reduced the duration of
arrhythmias (12-14). The findings that the basal heart
rate decreased in the glibenclamide group in respect of
the control group contradicts the results of El-Reyani et
al. (6), who suggested that the basal heart rate increased
in anesthetized rats treated with the same dose of
glibenclamide alone. This discrepancy may be due to the
animal model used in the latter study. Hypoglycemiainduced adrenergic activation may cause reflex
bradycardia following tachycardia in these groups.
However, although hypoglycemia was also observed in
the combination group, similarly to the glibenclamide
treated animals, heart rate did not decrease. This may
underline another mechanism that caused the lowered
heart rate in the glibenclamide group apart from
hypoglycemia. The sympathetic nerve endings in the atria
have been shown to contain ATP sensitive potassium
channels, in which glibenclamide (a blocker of ATP
sensitive potassium channels) and pinacidil (an opener of
ATP sensitive potassium channels) increased the resting
release of norepinephrine (17). This result may indicate
that the lowering of the heart rate in the glibenclamide
treated group in our study is caused by the modulation of
norepinephrine release from atrial sympathetic nerve
endings. Yohimbine, either alone in a higher dose or in
combination with glibenclamide, may enhance the release
of norepinephrine from sympathetic nerve endings before
coronary ligation. This may be a reason for the higher
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Table 4. The duration of arrhythmias observed at the end of 15 min and infarct size at 16 h following coronary ligation in surviving animals.
Mean±Standart error
Duration of arrhythmias (seconds)
N
VF

VT

Others

Total

N

Infarct size

Glibenclamide 5 mg/kg (b)

8

3 ±1

51 ± 32

62 ±17

193 ± 102

7

26 ± 7

Yohimbine 1 mg/kg (c )

5

10 ± 6

25 ± 20

21 ±6

57 ± 24

4

30 ± 4

Yohimbine 5 mg/kg (d)

6

21 ± 21

16 ± 10

8 ±6

46 ± 34

6

13 ± 8*

Glibenclamide 5 mg/kg + Yohimbine 1 mg/kg (e)

6

2 ± 0,8

63 ± 19

48 ±8

113 ± 24

6

26 ± 7

Glibenclamide 5 mg/kg + Yohimbine 5 mg/kg (f)

6

15 ± 8

65 ± 22

79 ±19

159 ± 41

5

33 ± 6

*P = 0.06

Table 5. Blood glucose levels after 25 min of drug administration.
Group

Dose
(mg/kg)

Control

Glucose,
mg/100 ml blood
93 ± 5.3

Glibenclamide

5

75 ± 2.5***

Yohimbine

1

102 ± 4.2

Yohimbine

5

102 ± 2.9

Glibenclamide+Yohimbine

5+1

61 ± 4.6***

Glibenclamide+Yohimbine

5+5

48 ± 4***

Results are mean ± S.E. of 5 animals in each group
***P < 0.001 compared to the corresponding control value

heart rate observed before ligation in these groups
compared to the glibenclamide treated animals. A lower
dose of yohimbine was not effective against arrhythmias
(18). This may be caused by less norepinephrine release.
We did not find any comparable studies in which the
combined effect of glibenclamide and yohimbine on
arrhythmias following coronary ligation had been
investigated. Metoprolol, a cardioselective β-blocker
when used in combination with glibenclamide, was
protective against the development of life-threatining
arrhythmias during the acute phase of experimental
myocardial infarction in conscious rats in one study (10).
This result indicates that metoprolol lowers myocardial
contractility and increases coronary vasodilatation and so
reduces the ischemic effect of glibenclamide. In contrast
to metoprolol, yohimbine alone reduced the duration of
arrhythmias. The opposite effect of yohimbine may be

attributed, rather than to the lowered heart rate, to
myocardial catecholamine release from adrenergic nerve
endings (12). In combination with glibenclamide, it was
not as effective on the severity of arrhythmias as
glibenclamide in combination with metoprolol. However
the survival rate following 16 h of infarction increased in
the combination with 1 mg/kg of yohimbine, although it
did not reduce the incidence or duration of ventricular
fibrillation. On the other hand, the combination of a
higher dose of glibenclamide reduced ventricular
fibrillation nonsignificantly, but did not affect the survival
rate 16 h following ligation. The underlying mechanism in
the higher survival rate in the 1 mg/kg yohimbine
combination cannot be identified in the present study. It
can however, be said that the higher dose of yohimbine
may cause greater catecholamine release and potentiate
the ischemic effect of glibenclamide.
The suggestion that catecholamine release due to
hypoglycemia induced by glybenclamide before coronary
ligation may protect against arrhythmia was supported by
the results of this study (19). Since in combination
hypoglycemia and yohimbine can cause catecholamine
release and may precondition the heart. This explanation
is likely to account for the visible decreased survival rate
and lethal arrhythmia in the combination group with 1
mg/kg of yohimbine. The greater catecholamine release
may adversely influence these effects and cause more
arrhythmia and a lowered survival rate.
The results of the present study can also be compared
with our previous research that used the same animal
model (18). In this study, the lower arrhythmia score in
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the group given a higher dose of yohimbine was similar
to the effect of epinephrine on the arrhythmias
pretreated before coronary ligation. Low doses of
yohimbine and epinephrine in both studies had no effect
on arrhythmias. This means that the lower dose of
yohimbine did not cause enough catecholamine release;
therefore, it did not induce adrenergic preconditioning.
Similar protection against arrhythmia during coronary
artery occlusion was also mentioned in a recent study
(20).

glibenclamide or yohimbine induced synergistic
catecholamine release may provide adrenergic
preconditioning before coronary ligation and may
increase survival rates and reduce the arrhythmic period.
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The combination of glibenclamide with yohimbine is
not particularly protective against arrhythmias.
Yohimbine by itself reduces the infarct size and
arrhythmia score, but not with glibenclamide. Either
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